ロード中...
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
BACKGROUND:Hepatitis C is the second fastest growing infectious disease in China. The standard-of-care for chronic hepatitis C in China is Pegylated interferon plus ribavirin (PR), which is associated with tolerability and efficacy issues. An interferon- and ribavirin-free, all-oral regimen comprisi...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Public Library of Science (PLoS)
2018-01-01
|
| シリーズ: | PLoS ONE |
| オンライン･アクセス: | http://europepmc.org/articles/PMC5892899?pdf=render |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|